JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Stryker Corp

Gesloten

SectorGezondheidszorg

360.47 0.16

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

356.48

Max

368.57

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

849M

Verkoop

1.1B

7.2B

K/W

Sectorgemiddelde

43.878

84.243

EPS

4.47

Dividendrendement

0.92

Winstmarge

11.839

Werknemers

53,000

EBITDA

351M

1.7B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+17.4% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.92%

2.28%

Volgende Winsten

30 apr 2026

Volgende dividenddatum

29 apr 2026

Volgende Ex Dividend datum

30 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

4.3B

141B

Vorige openingsprijs

360.31

Vorige sluitingsprijs

360.47

Nieuwssentiment

By Acuity

23%

77%

54 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Stryker Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jan 2026, 22:05 UTC

Winsten

Stryker Logs Higher 4Q Profit On Sales Gains

30 okt 2025, 20:36 UTC

Winsten

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

31 jul 2025, 20:42 UTC

Winsten

Stryker Lifts Guidance on Improving Tariff Outlook

1 mei 2025, 20:56 UTC

Winsten

Stryker Lowers Adjusted EPS View on $200 Million Tariff Impact

30 jan 2026, 17:03 UTC

Marktinformatie

Stryker's 4Q Results Signal 2026 Growth -- Market Talk

29 jan 2026, 21:07 UTC

Winsten

Stryker Sees 2026 Organic Net Sales Growth 8%-9.5%

29 jan 2026, 21:05 UTC

Winsten

Stryker 4Q Adj EPS $4.47 >SYK

5 nov 2025, 19:38 UTC

Winsten

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

5 nov 2025, 17:00 UTC

Winsten

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

30 okt 2025, 20:21 UTC

Winsten

Stryker Lifts FY Sales View After 3Q Revenue Rises

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Adj EPS $3.19 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q EPS $2.22 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Sales $6.1B >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Net $859M >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker Sees FY Adj EPS $13.50-Adj EPS $13.60 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Adj EPS $3.19 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Net $859M >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Sales $6.06B >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q EPS $2.22 >SYK

31 jul 2025, 20:09 UTC

Winsten

Stryker Estimates Net Impact From Tariffs in 2025 of Approximately $175M

31 jul 2025, 20:09 UTC

Winsten

Stryker Sales >SYK

31 jul 2025, 20:09 UTC

Winsten

Stryker Sees FY25 Organic Net Sales Up 9.5%-10%

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Sales $6B >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Net $884M >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker Sees FY Adj EPS $13.40-Adj EPS $13.60 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Adj EPS $3.13 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Sales $6B >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q EPS $2.29 >SYK

Peer Vergelijking

Prijswijziging

Stryker Corp Prognose

Koersdoel

By TipRanks

17.4% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 432.21 USD  17.4%

Hoogste 469 USD

Laagste 387 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Stryker Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

18

Buy

3

Hold

0

Sell

Technische score

By Trading Central

373.92 / 383.99Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

54 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
help-icon Live chat